Euryzam

The Kiev company PJSC Farmak (Ukraine) introduced the drug Evrizam to the pharmaceutical market, which is included in the International Register in the pharmacotherapeutic group of psychostimulants and nootropic drugs.

Indications Euryzam

The component content of the drug, the direction of the pharmacodynamics of the drug in question determine the indications for the use of Evrizam.

• Atherosclerosis, which affects the capillaries of the brain, leading to a failure of normal blood circulation in this area of the human body.
• Consequences of traumatic brain injury.
• Impaired ability to concentrate.
• Ischemic stroke, as well as the time of rehabilitation therapy after a hemorrhagic crisis, which led to deterioration of cerebral circulation.
• Problems with structural and logical thinking.
• Problems with short-term and long-term memories.
• Emotional instability: irritability, panic, depression.
• Encephalopathy, which develops for various reasons, is a pathological lesion of the brain due to the death of nerve cells, which is caused by a disruption in blood supply and oxygen deficiency.
• Meniere's syndrome is a disease of the inner ear that causes an increase in the amount of fluid (endolymph) in its cavity.
• Labyrinthopathy is a pathology of the inner ear caused by degenerative changes in its neural elements and manifested by hearing impairment and various vestibular disorders.
• Dizziness.
• The feeling of a constant background noise in the ears.
• Nausea, which, if intense, develops into gag reflexes.
• Nystagmus is an involuntary movement of the eyeballs.
• Preventive measures to relieve kinetosis - a pathological condition caused by an inadequate response of the vestibular apparatus to external, completely normal stimuli.
• As a preventative measure against frequent migraines.
• As a supportive therapy to improve memory and learning in special children with intellectual disabilities.

Release form

There are two main active substances in the composition of the presented medicinal product: cinnarizine and piracetam. They are the ones that dictate the direction of the medicinal product's action, giving it its characteristics.

The drug is available in capsules, which are presented by a hard gelatin shell. The capsule itself consists of two halves: the main component is white, and the "lid" has a slightly beige color. The container is filled with a crystalline powder of pure white or slightly tinted color.

One unit of the medicine contains, in terms of absolutely dry product (0% humidity), cinnarizine - 0.025 g, piracetam - 0.4 g. The capsules of the drug Evrizam have, in addition to the active ones, additional chemical compounds that allow maintaining or enhancing the necessary characteristics of the basic components. Such chemical compounds include lactose monohydrate, magnesium stearate, aerosil (anhydrous colloidal silicon dioxide).

Pharmacodynamics

The drug in question is a psychostimulant and nootropic drug and is made so by the pharmacodynamics of Evrizam - a harmonious combination of all components of the drug. Evrizam is a combined mixture with two main basic components that are responsible for activating the flow of blood through the capillary system of the brain, improving the metabolism of this area of the human body.

Piracetam, of which there are 400 mg in one capsule, is a neurometabolic stimulant (nootropic agent), which is designed to provide a specific effect on the higher functions of the brain. It works as a stimulator of brain activity, which rejuvenates the body and prolongs life. The work of piracetam is aimed at improving the energy potential. Thanks to it, blood microcirculation in areas of the brain that have undergone pathological changes is improved. This chemical compound improves the course of oxidation-reduction processes in ischemic tissues of the brain region, activates metabolic processes. Piracetam stabilizes, has a positive effect on the integrative functions of the brain, consolidates the patient's memory, makes it possible to improve learning ability.

Cinnarizine eliminates the effect of histamine on H1-histamine receptors by the mechanism of competitive inhibition, and also effectively suppresses the work of calcium channels. This chemical compound is an excellent substance that works on the expansion of blood vessels, showing its activity mainly on the coronary and cerebral capillaries of the circulatory system. This chemical compound has a strong effect on smooth muscles, of which the vessels consist. Cinnarizine is a substance that weakens the effect of some endogenous vasoconstrictors, such as angiotensin or norepinephrine, showing the opposite effectiveness. This drug enhances the vasodilatory effect of nitrogen dioxide on the capillaries of the brain. At the same time, no effect on human blood pressure and myocardial conductivity has been revealed. It has a calming effect on the excitability of the vestibular apparatus. Cinnarizine improves the elasticity of the vessel walls, thins the blood well, reducing its viscosity, which protects capillaries from thrombosis. Due to the blocking of the H1 activity of histamine receptors, it shows minor sedative properties. This chemical compound dampens long-term excitation of sympathetic nerve centers, improves the resistance of tissue cells to possible oxygen deficiency.

When working together, cinnarizine and piracetam mutually enhance each other's antihypoxic properties quite well. Tandem toxicity does not show a level higher than the negative impact of its individual components.

Pharmacokinetics

This combined drug is absorbed by the gastrointestinal mucosa in a short time and almost completely. The high pharmacokinetics of Evrizam, based on the individual characteristics of the patient's body, allows you to achieve the necessary therapeutic effect after an hour to six hours, reaching maximum concentration in the blood.

Piracetam does not form any compounds with blood serum proteins and is not subject to metabolism, but at the same time has an excellent diffusion ability. This component of Eurysam is almost completely utilized from the human body without changes within thirty hours after administration.

Cinnarizine is also perfectly absorbed by the mucous membrane, and it is enough for an hour to four hours to pass and its quantitative component reaches a maximum not only in the serum. A high concentration of this chemical compound is also determined in the lung tissue, cells of the spleen, liver, brain, heart, kidneys, spleen. The binding characteristic of cinnarizine with proteins, which are one of the components of blood plasma, is quite high and amounts to 91%. Metabolization of this component occurs almost entirely in the liver. A third of all metabolites are excreted through the urinary tract with urine, the rest with feces comes out through the intestines. The half-life T1 / 2 for this drug is four hours.

Dosing and administration

To achieve the desired effect, it is advisable to administer the pharmacological agent Evrizam orally after meals. The capsule should not be chewed. It is necessary to swallow it whole, softening the passage through the larynx with a sufficient amount of liquid. Usually, the method of administration and doses prescribed to an adult patient are one to two units of the drug, administered three times during the day. Teenagers and children who have already turned eight years old - one to two capsules one to two times a day.

The duration of the treatment course is determined by the attending physician, depending on the severity of the pathology, and can be from one to three months. You should not constantly use Evrizam for more than three months. If there is a medical need, you should take a break and then take another therapeutic course. Two or three courses are acceptable during the year.

[ 1 ]

Use Euryzam during pregnancy

Due to the weak research base, insufficient monitoring and a small package of clinical analysis results, there is no confirmed data on the safety of the drug in question. Therefore, the use of Evrizam during pregnancy and breastfeeding is not recommended.

It is worth noting that this drug, based on its pharmacodynamics, is not recommended for use in children under eight years of age. The drug should also be taken with particular caution by people who drive vehicles or operate complex, dangerous moving mechanisms. These warnings are based on the possibility of side effects.

Contraindications

Such a striking effect on the human body and the chemical basis of the drug cause situations when this drug can cause more damage to the patient's body than benefit it. Contraindications to the use of Evrizam are determined by several points.

• Increased intolerance of the patient's body to piracetam, cinnarizine, its metabolites, similarly to pyrrolidone formations and/or to additional substances included in the composition of Eurysam.
• Parkinson's disease.
• Increased psychomotor excitability.
• Apoplexy of a hemorrhagic nature, causing a fairly serious deviation from the norm of blood circulation indicators in the tissues of the brain.
• Severe phase of renal dysfunction (creatinine clearance below 20 ml per minute).
• Glaucoma is high intraocular pressure.
• Huntington's chorea is a genetic disease of the nervous system, characterized by a progressive course with degeneration.
• The period of pregnancy and lactation.
• Children under 8 years of age.

You need to know:

1. The presence of the active component, cinnarizine, in the composition of Eurysam can show a false-positive result during anti-doping control during competitions in athletes. It can also affect the result of test samples when identifying an allergic irritant.
2. If a person has a hereditary, quite rare, pathology caused by individual intolerance to galactose-glucose malabsorption, galactose, lactose - this should be a contraindication to the use of Evrizam, since it contains lactose.
3. If sleep disorders and tension are observed during therapy with “pure” piracetam, this problem can be solved by prescribing Eurysam instead as monotherapy.
4. Consumption of alcoholic beverages during treatment with Eurysam is not allowed.
5. The drug should be prescribed with great caution to patients with a history of hemostasis disorders. Taking the drug may cause bleeding. The drug should not be administered in the postoperative period or if the patient has problems with blood clotting.
6. If the patient has a certain degree of renal dysfunction, the prescribed dosage is reduced, and the interval between doses is adjusted. If there are problems with the liver, the level of the enzyme produced by the liver should be constantly monitored.
7. If the patient has a history of cortical myoclonus, do not suddenly stop taking the medication - this may result in the resumption of pathological seizures.
8. People of retirement age are recommended to periodically monitor the level of renal function during therapy with Evrizam; if necessary, the dosage of the drug is adjusted.

Side effects Euryzam

Incorrect use of the drug and individual characteristics of the patient can provoke the body to respond with unpleasant symptoms. In such a situation, side effects of Evrizam can be observed, which are manifested by such symptoms:

• NS reaction:
  • Hyperkinesia is an increase in the motor activity of an internal organ, a state of increased excitability due to a violation of muscle tone and nerve impulse conduction.
  • Sleep disturbance.
  • Headache.
  • Increased excitability.
  • Confusion of consciousness.
  • If there is a predisposition - epileptic seizures.
  • Ataxia is a disorder in which the movements of different muscles are coordinated in the absence of muscle weakness.
  • Depressive states.
  • Hallucinations.
  • Malfunction of the vestibular system.
• Gastrointestinal reaction:
  • Digestive upset.
  • Nausea, which may cause a gag reflex.
  • Cholestatic jaundice.
  • Painful symptoms that can manifest in both the upper and lower abdomen.
• The immune system's response is increased sensitivity of the body to the "aggressor", anaphylaxis, acute allergic pathology of the skin.

• Dermal reaction:
  • Swelling.
  • Itching and irritation.
  • Various dermatitis.
  • Hives.
  • Photosensitivity is the intolerance of the patient’s epidermis to the sun’s ultraviolet rays.
  • Lichen planus.
  • Rashes.
  • Lupus-like symptoms.
• Other side effects of Evrizam:
  • Weight gain.
  • Increased blood pressure.
  • Thrombophlebitis.
  • Increased sweating.
  • High body temperature.

If one or more symptoms from this list appear, you should stop taking Eurysam and consult your doctor, informing him of your body's reaction.

Overdose

Any pharmacological agent must be taken strictly according to the instructions, which clearly describe the dosages and conditions of administration. If for some reason an overdose of the drug was allowed, the patient's body may manifest itself with response symptoms. Evrizam can be overdosed mainly in the case of pediatric treatment.

• Sleep disorders: insomnia, anxiety, nightmares.
• Children may develop unfounded fears.
• Emotional instability: sometimes irritability, sometimes euphoria.
• Tremor is a movement disorder associated with involuntary muscle contractions.
• The appearance of mild hallucinations.
• Spasms and cramps.

In such a situation, you should stop taking the drug and notify your doctor, who, after assessing the situation, will prescribe symptomatic therapy.

Interactions with other drugs

It is necessary to be quite careful when taking different medications together. For example, the interaction of Evrizam with other drugs can cause an increase in the sedative properties of chemical compounds that depress the receptors of the central nervous system. The same reaction occurs with the tandem administration of Evrizam with hypotensive or nootropic pharmacological drugs. Medicines aimed at expanding the vascular system integrate the action of Evrizam, while vasoconstrictor chemical compounds reduce its pharmacokinetics.

[ 2 ]

Storage conditions

To ensure that the medicinal product does not lose its pharmacological properties, it is necessary to strictly follow the storage conditions specified in the instructions included with the Evrizam packaging:

• The temperature in the room where the medicine is located should not exceed 25 °C.
• The air in the room should have low humidity.
• The storage area must be protected from light, especially from direct sunlight.
• The medicine should not be accessible to children.

Shelf life

If all the requirements for storing the drug are met, the shelf life of Eurysam is two years. These parameters are necessarily reflected on the packaging. In case of changes in storage conditions, the therapeutic effectiveness of the drug is significantly reduced, and the period of effective use is reduced. If the expiration date of the drug has expired, it is unacceptable to continue using it, instead of the expected positive effect, you can get the opposite result.